This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information

EXPERT INSIGHTS

RESOURCES

See what the experts are saying about treatment with NINLARO® (ixazomib)

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

NOW PLAYING

The importance of long-term* proteasome inhibition in multiple myeloma

NOW PLAYING

Oral proteasome inhibition in the evolving multiple myeloma treatment landscape

  • *Defined as treatment to progression or unacceptable toxicity.
  • Dr. Niesvizky and Dr. Vescio are paid consultants of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • This content is intended for informational purposes only and is not a substitute for your clinical knowledge or professional judgment.